{"links":{"html":"https://www.erudio.com/reports/harmoni-gi3-nct07228832","json":"https://www.erudio.com/reports/harmoni-gi3-nct07228832.json","markdown":"https://www.erudio.com/reports/harmoni-gi3-nct07228832.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"harmoni-gi3-07228832"}},"request":"https://www.erudio.com/contact?report=harmoni-gi3-07228832"},"offer":{"cited_commentary_sources":10,"verified_hcp_statements":19,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":3,"optional":true,"price_per_verified_person_usd":15,"price_usd":45,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"harmoni-gi3-nct07228832"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=harmoni-gi3-07228832","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/harmoni-gi3-nct07228832","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T00:41:11.492609Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":13,"no_commentary_found":1},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":2,"title":"Primary endpoint: PFS by IRRC based on RECIST v1.1"},{"claim_count":2,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.secondaryOutcomes[0]","source_count":2,"title":"Secondary endpoint: Overall Survival (OS) in the population"},{"claim_count":4,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes[1]","source_count":4,"title":"Secondary endpoint: ORR"},{"claim_count":2,"coverage":"discussed","id":"T4","registry_field":"outcomesModule.secondaryOutcomes[2]","source_count":2,"title":"Secondary endpoint: Adverse Events (AE)"},{"claim_count":0,"coverage":"no_commentary_found","id":"T5","registry_field":"outcomesModule.secondaryOutcomes[3]","source_count":0,"title":"Secondary endpoint: DoR"},{"claim_count":9,"coverage":"discussed","id":"T6","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":7,"coverage":"discussed","id":"T7","registry_field":"armsInterventionsModule.armGroups","source_count":7,"title":"The comparison"},{"claim_count":2,"coverage":"discussed","id":"T8","registry_field":"outcomesModule","source_count":2,"title":"Safety and tolerability"},{"claim_count":4,"coverage":"discussed","id":"T9","registry_field":"designModule","source_count":4,"title":"Design and conduct"},{"claim_count":5,"coverage":"discussed","id":"A1","source_count":2,"title":"Disease control and interpretation of the precursor phase II signal"},{"claim_count":7,"coverage":"discussed","id":"A2","source_count":3,"title":"Dual-targeting rationale and HARMONi-6/HARMONi-2 precedent"},{"claim_count":2,"coverage":"discussed","id":"A3","source_count":2,"title":"Local trial access and site participation"},{"claim_count":4,"coverage":"discussed","id":"A4","source_count":4,"title":"Strategic, commercial and patent-related interpretations"},{"claim_count":1,"coverage":"discussed","id":"A5","source_count":1,"title":"Competitive endpoint-design comparisons"}],"counts":{"cited_sources":10,"claims_by_expression_type":{"comparison":2,"experience":1,"interpretation":6,"opinion":1,"question":1,"restatement":5,"uncertainty":2,"unspecified":1},"claims_by_kind":{"source_observation":19},"clinician_statements":7,"evidence_units":13,"findings":5,"organisational_accounts":2,"people_cited":7,"people_identity_verified":3,"people_total":8,"screened_sources":28,"verified_claims":19},"depth":"thin","findings_index":[{"id":"F1","structure":{"claims":7,"claims_by_group":{"comparisons":0,"experience":0,"questions":2,"restated":4,"views":1},"has_counterview":false,"limitations":4,"links":{"context":1,"support":7},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"Early efficacy enthusiasm remains conditional on confirmation and needs its phase II safety context"},{"id":"F3","structure":{"claims":1,"claims_by_group":{"comparisons":1,"experience":0,"questions":0,"restated":0,"views":0},"has_counterview":false,"limitations":2,"links":{"context":0,"support":1},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"A competitive endpoint comparison raises an unresolved question about what 'having OS' means"},{"id":"F4","structure":{"claims":7,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":1,"views":4},"has_counterview":false,"limitations":2,"links":{"context":1,"support":7},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Dual targeting and lung-cancer precedent motivate attention, while clinical synergy remains an open question"},{"id":"F5","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":0,"views":1},"has_counterview":false,"limitations":2,"links":{"context":0,"support":2},"ma_question":true,"named_voices":2,"passages":2,"sources":2,"sources_by_kind":{"commentary":2}},"title":"Investigator enthusiasm is connected to local trial participation, with different stated stages of access"},{"id":"F6","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":1,"views":2},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":3,"passages":3,"sources":3,"sources_by_kind":{"commentary":3}},"title":"Pipeline and valuation enthusiasm is distinct from a judgment of patient benefit"}],"medical_affairs_question":"What would establish clinically meaningful added benefit over bevacizumab plus mFOLFOX6, with a tolerability trade-off patients can understand?","sections":{"analysis":[{"id":"section-1","level":2,"title":"Early enthusiasm remains conditional on confirmation"},{"id":"section-2","level":3,"title":"Safety descriptions belong alongside that early-signal enthusiasm"},{"id":"section-3","level":2,"title":"The OS comparison is consequential but its endpoint scope is unclear"},{"id":"section-4","level":2,"title":"Mechanistic interest and lung precedent do not settle colorectal synergy"},{"id":"section-5","level":2,"title":"Local participation gives enthusiasm a practical, research-access meaning"},{"id":"section-6","level":2,"title":"Strategic value is not a clinical efficacy conclusion"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase3","trial_dimensions":[{"findings":[{"id":"F1","shared_claims":3}],"id":"T1","label":"Primary endpoint: PFS by IRRC based on RECIST v1.1"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1}],"id":"T2","label":"Secondary endpoint: Overall Survival (OS) in the population"},{"findings":[{"id":"F1","shared_claims":4}],"id":"T3","label":"Secondary endpoint: ORR"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T4","label":"Secondary endpoint: Adverse Events (AE)"},{"findings":[],"id":"T5","label":"Secondary endpoint: DoR"},{"findings":[{"id":"F1","shared_claims":6},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":1},{"id":"F6","shared_claims":1}],"id":"T6","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":3},{"id":"F4","shared_claims":2},{"id":"F5","shared_claims":2},{"id":"F6","shared_claims":1}],"id":"T7","label":"The comparison"},{"findings":[{"id":"F1","shared_claims":2}],"id":"T8","label":"Safety and tolerability"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1},{"id":"F5","shared_claims":2}],"id":"T9","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T00:41:11.492609Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T00:57:23Z","record_hash":"75172cb3f72f70fe07bf4dc91b5da9218b948891822bce13effedb13a2b170e8","release_hash":"2745303c2e784efcd543b57131b9ea8b3fa3c64f434fa83926430219d0e0660e","report_id":"erudio-nct07228832","run_id":"3d402c7a-809f-43ac-9b0e-c4a3cc2b8134","schema_version":"5.0","slug":"harmoni-gi3-07228832","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"HARMONi-GI3 asks whether ivonescimab plus FOLFOX improves first-line metastatic colorectal cancer treatment compared with bevacizumab plus FOLFOX. Clinicians in the sources reviewed for this edition express conditional enthusiasm about early efficacy. Dual targeting attracts interest, while clinical synergy draws questions and safety interpretation needs context. Confirmation of comparative clinical benefit remains unresolved, alongside practical questions about local trial participation and patient access.","meta_description":"28 sources screened · 19 verified statements (7 from clinicians verified by NPI or staff page) from 10 sources · 5 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-e28640deecaf4388cf82"],"id":"F3","paraphrase":"An X-thread post asks what prompted a change in overall-survival endpoint selection in a competing colorectal-cancer trial.","publication_caveats":{"reason":"The source has a short-quotation and link-out policy; additional publication caveats are not specified.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-05-06","title":"A competitive endpoint comparison raises an unresolved question about what 'having OS' means"}]},"publication":{"approved_at":"2026-10-29T00:57:23Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":28},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","11 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The public posts reviewed do not establish consensus, the prevalence of a view among HCPs or how clinicians are treating patients in routine practice.","Some authors have confirmed physician identities, while others have unverified identities or an unresolved clinical role. An organizational relay and commercial commentary should not be counted as additional independent HCP judgments.","Discussion using unnamed references or different wording may be absent, and some passages were not fully assessed for clinician views. An aspect with no commentary therefore describes only what was identified in the sources reviewed for this edition.","No full protocol or results publication for the exact trial was available among the sources reviewed, and exact product-label information was unavailable. Detailed endpoint specifications, approved-use questions and comparative outcomes cannot be settled from these comments.","The reported colorectal efficacy and safety figures are phase II evidence, not HARMONi-GI3 results. Lung-cancer studies are invoked as motivation, not as evidence of efficacy in metastatic colorectal cancer.","Post dates identify when comments were published, not when a session, readout or site activation occurred. They do not establish changes of mind or disagreement across settings."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":8,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":10},"count":10,"evidence_window":{"end":"2026-09-19","start":"2025-10-20"},"retrieval_snapshot":"2026-10-29T00:18:09.324360Z","timeline":[{"count":2,"week":"2025-W43"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W19"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W37"},{"count":1,"week":"2026-W38"}],"undated_sources":0},"quote_policies":[{"id":"clinicaltrials:NCT07228832:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07228832:context","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-ffhfzwr3igtwt4y7zdompvjv-3m3f4m6avew2h","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-tsqfr6zfxr7jcxoceowmozu4-3mph3zslylp27","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-wef5q2r4evg4f47gq452qwdk-3mymc6auqb22p","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7407619343943094272","quote_policy":"short_quote_link_out"},{"id":"mcp:linkedin_post:7495507521525379073","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979140587593908584:b7763440-ebc6-40cd-859e-9595bac5614d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979140614370320832:9b85acef-2aca-4ea4-8acf-4f44ee6bfcbf","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979140842691457348:59a5bb94-0009-420f-8824-f04b3173cd6b","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979183707937247668:82ddfa5a-a97b-4e20-8f88-d69a9bb7d843","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979248282632143257:5296c91e-3ff6-435a-8ff1-eaa52363cb7f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979500722883375269:ed97074a-588f-4157-8d8b-36a825fdbaa5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980230982562455953:da67ddff-5d9d-4df7-8785-c18215c47e92","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980299235703820620:7e9bdc11-c2fb-494e-918a-be45d38217a6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980494428696682894:e1103225-b8b7-4c10-81d1-66e530e5e507","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980538069792235993:5c66daa0-2f4a-4a3b-acab-a59bf649355d","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1980995965114089628:046124bb-b27b-4e6b-8b74-81722f59e5fe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1981313973203911067:ac3af434-e68b-4250-90f9-8092c823b1e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1989714481061257605:3e4e8a7d-73d2-4115-a835-33e83c35bce6","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2052103699221061634:267e9bf0-91f5-4d8e-b61b-31a813252288","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061179248405033325:25fff6b8-4daf-4dd4-9fb7-f02e1f6fcf8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061205193941815781:01dde4ec-da8f-4c89-89ac-c89ebd51e4d2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2061402281031987564:3dbd6530-e6b8-4781-9f97-22235d8d48a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099135375029522818:0955f990-ac7c-468f-b311-975b44a5ee4f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2100633117572911226:9d42cb83-8408-4ead-beaa-9376be65edf0","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101280971115127104:78bc7ec2-fff3-4901-a588-23c43132bb65","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2106382651418615942:0710b7ec-cfb0-492d-9911-4227d1b2a13c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114401724714934556:528f7df1-86e5-43d8-bdbb-189a9b61608f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114402745406939519:f8d9dcf0-0018-456a-9bca-093d9ef61873","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":3,"linkedin_post":2,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":23,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":28},"count":28,"evidence_window":{"end":"2026-10-25","start":"2025-10-17"},"retrieval_snapshot":"2026-10-29T00:18:09.498789Z","timeline":[{"count":7,"week":"2025-W42"},{"count":6,"week":"2025-W43"},{"count":1,"week":"2025-W46"},{"count":1,"week":"2025-W51"},{"count":1,"week":"2026-W19"},{"count":2,"week":"2026-W22"},{"count":1,"week":"2026-W23"},{"count":1,"week":"2026-W27"},{"count":1,"week":"2026-W34"},{"count":1,"week":"2026-W37"},{"count":2,"week":"2026-W38"},{"count":1,"week":"2026-W40"},{"count":3,"week":"2026-W43"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: drug: ivonescimab injection","status":"unmapped"},{"reason":"Unmapped registry intervention: drug: bevacizumab injection","status":"unmapped"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Colorectal cancer","slug":"colorectal-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"HARMONi-GI3","aliases":["HARMONi-GI3","Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer"],"brief_title":"Phase III Study of Ivonescimab or Bevacizumab Combined With FOLFOX in Patients With Metastatic Colorectal Cancer","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Metastatic Colorectal Cancer (CRC)"],"enrollment":{"count":600,"type":"ESTIMATED"},"interventions":[{"name":"Drug: Ivonescimab Injection","synonyms":["Oxaliplatin","Leucovorin","5-Fluorouracil"],"type":"DRUG"},{"name":"Drug: Bevacizumab Injection","synonyms":["Oxaliplatin","Leucovorin","5-Fluorouracil"],"type":"DRUG"}],"nct_id":"NCT07228832","official_title":"A Randomized, Active-Controlled, Double-blind, Multicenter, Phase 3 Clinical Study of Ivonescimab in Combination With FOLFOX Versus Bevacizumab in Combination With FOLFOX for the First-line Treatment of Metastatic Colorectal Cancer","overall_status":"RECRUITING","phase":["PHASE3"],"primary_completion_date":{"date":"2028-05-31","type":"ESTIMATED"},"primary_endpoints":[{"description":"Progression-free survival (PFS) assessed by IRRC per RECIST v1.1","measure":"PFS by IRRC based on RECIST v1.1","timeFrame":"Up to approximately 2.5 years"}],"registry_last_updated":"2026-10-06","registry_url":"https://clinicaltrials.gov/study/NCT07228832","short_name":"HARMONi-GI3","short_name_basis":"registry_acronym","sponsor":"Summit Therapeutics","start_date":{"date":"2025-11-18","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase3","study_ids":[{"id":"SMT112-3005","type":"sponsor_study_id"}],"study_type":"INTERVENTIONAL"}}}